Video

HER2+ mBC: DESTINY-Breast04 Trial

The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.

The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.